Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (10)
Type
(
1 selected
)
Type
Guidance (295)
Quality standard (31)
Guidance programme
Guidance programme
Diagnostics guidance (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (6)
Medical technologies guidance (7)
Technology appraisal guidance (280)
Apply filters
Showing 91 to 100 of 295
Type: Guidance
Remove Type: Guidance filter
Guidance and quality standards awaiting development
Title
Type
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over TS ID 11847
Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]
Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]
Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]
Technology appraisal guidance
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID 6463
Technology appraisal guidance
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015
Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 ID4037
Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]
Technology appraisal guidance
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806
Technology appraisal guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]
Technology appraisal guidance
Previous page
1
…
8
9
Current page
10
11
12
…
30
Page
10
of
30
Next page
Results per page
10
25
50
All
Back to top